Drug Profile
NT 157
Alternative Names: NT157Latest Information Update: 07 Sep 2023
Price :
$50
*
At a glance
- Originator Hebrew University of Jerusalem
- Developer TyrNovo
- Class Small molecules
- Mechanism of Action Insulin receptor substrate protein inhibitors; STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Malignant melanoma; Osteosarcoma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer
Most Recent Events
- 07 Sep 2023 Discontinued - Preclinical for Colorectal cancer in Israel (IV)
- 07 Sep 2023 Discontinued - Preclinical for Malignant melanoma in Israel (IV)
- 07 Sep 2023 Discontinued - Preclinical for Ovarian cancer in Israel (IV)